SANDERLING VENTURES MANAGEMENT V 4/A
4/A · ENDOCYTE INC · Filed Mar 9, 2011
Insider Transaction Report
Form 4/AAmended
ENDOCYTE INCECYT
SANDERLING VENTURES MANAGEMENT V
10% Owner
Transactions
- Conversion
Common Stock
2011-02-09+17,318→ 149,003 total(indirect: By Sanderling Ventures Management V)
Footnotes (4)
- [F1]Each share of the Issuer's Series A-1, Series A-2, Series B, Series C-1, Series C-2 and Series C-3 Preferred Stock automatically converted into shares of Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]The original Form 4 filing reported 44,502 shares held by Sanderling Ventures Management V were subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation (the "Restricted Stock Purchase Agreement"). This Amendment is being filed to report that only 5,235 shares held by Sanderling Ventures Management V are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement.
- [F3]Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
- [F4]Fred Middleton is the owner of Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership.